This inventor holds 1 USPTO granted patent. Top assignees: Baylor College of Medicine, Houston Methodist Research Institute, The United States Government. Active years: 2025.
Company Filing History:
1 out of 617 
1 out of 1 
1 out of 15 
Years Active: 2025
Title: Innovations by William Dalmeida, Jr.
Introduction
William Dalmeida, Jr. is an accomplished inventor based in League City, TX (US). He has made significant contributions to the field of mitochondrial dysfunction treatments through his innovative research and patented technologies. His work focuses on developing novel therapies that address oxidative and metal-related toxicities.
Latest Patents
William Dalmeida, Jr. holds a patent for "Acute and chronic mitochondrial electron transport chain dysfunction treatments and graphenic materials for use thereof." This patent includes modified hydrophilic carbon clusters (HCCs), poly(ethylene glycol)-hydrophilic carbon clusters (PEG-HCCs), and similarly structured materials like graphene quantum dots (GQDs). These materials have been enhanced with an iron chelating moiety, such as deferoxamine. By utilizing common binding sites, the carbon nanostructure facilitates intracellular transport, particularly in mitochondria. This innovation reduces oxidative breakdown of the chelator moiety prior to treatment and mitigates both the causes and consequences of metal-induced oxidative stress within the body. The graphenic materials developed can be used for treating acute and chronic mitochondrial electron transport chain dysfunction.
Career Highlights
Throughout his career, William has worked with prestigious institutions, including William Marsh Rice University and the University of Texas System. His research has led to advancements in understanding and treating mitochondrial dysfunction, showcasing his commitment to improving health outcomes through innovative solutions.
Collaborations
William has collaborated with notable colleagues, including James Mitchell Tour and Lizanne Nilewski. These partnerships have further enriched his research and contributed to the development of his patented technologies.
Conclusion
William Dalmeida, Jr. is a pioneering inventor whose work in mitochondrial dysfunction treatments has the potential to revolutionize therapeutic approaches to oxidative and metal-related toxicities. His innovative patents and collaborations highlight his significant contributions to the field.